Pneumococcal conjugate second or third-dose vaccines (PCVc) in Oman
Oman: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 99.0% in 2025. ▲ Rising
Latest (2025)
99.0%
Change on year
unchanged
World rank
1st
of 194 countries
All-time high
99.0%
in 2010
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Oman, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Oman recorded 99.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
Compared with earlier readings it is up 1.0% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Oman peaked at 99.0% in 2010 and was at its lowest, 0.0%, in 2008.
Oman ranks 1st of 194 countries on this measure, in the top 10%.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Oman, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 96.0% | — |
| 2010 | 99.0% | +3.1% |
| 2011 | 99.0% | +0.0% |
| 2012 | 99.0% | +0.0% |
| 2013 | 99.0% | +0.0% |
| 2014 | 98.0% | -1.0% |
| 2015 | 98.0% | +0.0% |
| 2016 | 99.0% | +1.0% |
| 2017 | 99.0% | +0.0% |
| 2018 | 99.0% | +0.0% |
| 2019 | 99.0% | +0.0% |
| 2020 | 99.0% | +0.0% |
| 2021 | 99.0% | +0.0% |
| 2022 | 97.0% | -2.0% |
| 2023 | 99.0% | +2.1% |
| 2024 | 99.0% | +0.0% |
| 2025 | 99.0% | +0.0% |
Oman compared with similar countries
- Oman's 99.0% is above the median for high income countries, which is 91.0%, 1.1× the median. (63 countries reporting)
- Oman's 99.0% is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 1.1× the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 48.0% | 0.0% | 96.0% | 2 |
| 2010s | 98.8% | 98.0% | 99.0% | 10 |
| 2020s | 98.7% | 97.0% | 99.0% | 6 |
Countries ranked near Oman
More health data for Oman
- Un projection of annual infant deaths, annual growth rate -0.8969 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.3507 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 429.2 deaths per 1,000 people (2090)
- Number of infants who die before age 1 221 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 1.89 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0388 units per person (2025)
- Population ages 00-04, male, annual growth rate 2.06 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Oman?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Oman was 99.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Oman?
- The highest recorded value was 99.0% in 2010.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Oman?
- The lowest recorded value was 0.0% in 2008.
- How does Oman rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Oman ranks 1st out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Oman?
- Over the last ten years it is up 1.0%. The long-run trend across the full record is rising.
- Where does this Oman data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).